España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Regenxbio
RGNX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$9.59
0.41
4.47%
At close: -
$9.45
-0.14
-1.46%
After Hours: Nov 22, 6:01 PM EDT
Get Report
Comment
Regenxbio (RGNX) Forecast
News
Earnings
Regenxbio (RGNX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Regenxbio (NASDAQ:RGNX) Stock
Regenxbio Stock (NASDAQ: RGNX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 21, 2024
HC Wainwright & Co. Maintains Buy on Regenxbi...
Benzinga Newsdesk
Wednesday, November 20, 2024
Chardan Capital Maintains Buy on Regenxbio, M...
Benzinga Newsdesk
Monday, November 18, 2024
What's Going On With REGENXBIO Shares Monday?
Dylan Berman
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
Avi Kapoor
Market-Moving News for November 18th
Benzinga Newsdesk
REGENXBIO shares are trading higher after the...
Benzinga Newsdesk
REGENXBIO Doses First Patient in Pivotal Tria...
Benzinga Newsdesk
Friday, November 15, 2024
5 Analysts Have This To Say About Regenxbio
Benzinga Insights
Morgan Stanley Assumes Regenxbio at Overweigh...
Benzinga Newsdesk
Thursday, November 07, 2024
HC Wainwright & Co. Maintains Buy on Regenxbi...
Benzinga Newsdesk
Regenxbio shares are trading higher after the...
Benzinga Newsdesk
Wednesday, November 06, 2024
Regenxbio Q3 EPS $(1.17) Misses $(1.12) Estim...
Benzinga Newsdesk
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Tuesday, October 22, 2024
Chardan Capital Maintains Buy on Regenxbio, M...
Benzinga Newsdesk
Monday, October 21, 2024
REGENXBIO Reports Phase II Data for Wet AMD G...
Benzinga Newsdesk
Thursday, October 10, 2024
What 4 Analyst Ratings Have To Say About Regenxbio
Benzinga Insights
Raymond James Reinstates Outperform on Regenx...
Benzinga Newsdesk
Tuesday, September 17, 2024
REGENXBIO Names Mitchell Chan As Executive Vi...
Benzinga Newsdesk
Wednesday, September 04, 2024
Assessing Regenxbio: Insights From 5 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Regenxb...
Benzinga Newsdesk
Tuesday, September 03, 2024
REGENXBIO Reports Data From Pivotal Dose Leve...
Benzinga Newsdesk
Tuesday, August 06, 2024
Wall Street Analysts Think Regenxbio Could Surge 234.37%: Read This Before Placing a Bet
Zacks
Monday, August 05, 2024
Barclays Maintains Overweight on Regenxbio, L...
Benzinga Newsdesk
Where Regenxbio Stands With Analysts
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Regenxbi...
Benzinga Newsdesk
Thursday, August 01, 2024
Regenxbio Q2 2024 GAAP EPS $(1.05) Beats $(1....
Benzinga Newsdesk
REGENXBIO Reports Clear Dose Response And Con...
Benzinga Newsdesk
Tuesday, June 25, 2024
Why Is Clearside Biomedical Stock Gaining Today?
Vandana Singh
Monday, June 24, 2024
REGENXBIO Expands Its AFFINITY DUCHENNE Trial...
Benzinga Newsdesk
Friday, June 21, 2024
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy
Vandana Singh
Thursday, June 20, 2024
HC Wainwright & Co. Reiterates Buy on Regenxb...
Benzinga Newsdesk
Tuesday, June 18, 2024
Regenxbio Concludes Pre-biologics License App...
Benzinga Newsdesk
Monday, June 17, 2024
Urogen Pharma Surges 9.7%: Is This an Indication of Further Gains?
Zacks
Wednesday, June 12, 2024
Regenxbio Reiterated Its Financial Guidance P...
Benzinga Newsdesk
REGENXBIO Announced That Curran Simpson, Chie...
Benzinga Newsdesk
Friday, June 07, 2024
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Vandana Singh
Assessing Regenxbio: Insights From 4 Financial Analysts
Benzinga Insights
Goldman Sachs Initiates Coverage On Regenxbio...
Benzinga Newsdesk
Wednesday, May 15, 2024
Evaluating Regenxbio: Insights From 9 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Maintains Buy on Regenxbi...
Benzinga Newsdesk
Wednesday, May 08, 2024
Regenxbio Q1 2024 GAAP EPS $(1.38) Misses $(1...
Benzinga Newsdesk
Friday, April 12, 2024
Where Regenxbio Stands With Analysts
Benzinga Insights
Stifel Maintains Buy on Regenxbio, Maintains ...
Benzinga Newsdesk
Thursday, March 28, 2024
REGENXBIO Announces Lancet Publication of Pha...
Benzinga Newsdesk
Monday, March 25, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Monday, March 11, 2024
HC Wainwright & Co. Initiates Coverage On Reg...
Benzinga Newsdesk
Friday, March 08, 2024
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
Vandana Singh
Regenxbio shares are trading higher after RBC...
Benzinga Newsdesk
RBC Capital Upgrades Regenxbio to Outperform,...
Benzinga Newsdesk
Thursday, March 07, 2024
Chardan Capital Maintains Buy on Regenxbio, M...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch